TY - JOUR
T1 - The safety of calcium channel blockers in human pregnancy
T2 - A prospective, multicenter cohort study
AU - Magee, L. A.
AU - Schick, B.
AU - Donnenfeld, A. E.
AU - Sage, S. R.
AU - Conover, B.
AU - Cook, L.
AU - McElhatton, P. R.
AU - Schmidt, M. A.
AU - Koren, G.
PY - 1996
Y1 - 1996
N2 - OBJECTIVE: Our purpose was to examine the potential teratogenicity of calcium channel blockers. STUDY DESIGN: Six teratogen information services prospectively collected and followed up 78 women with first-trimester exposure to calcium channel blockers. Pregnancy outcome was compared (by paired t test or χ2 analysis) with that of a control group matched for maternal age and smoking. RESULTS: There was no increase in major malformations (2/66 = 3.0% [calcium channel blockers] vs 0% [nonteratogenic controls], p = 0.27); a fivefold increase was ruled out (baseline 2%, α = 0.05, β = 0.20). The defects reported were attributable to maternal diabetes or coingestion of teratogens. The increase in preterm delivery (28% [calcium channel blockers] vs 9% [nonteratogenic controls], p = 0.003), attributed to maternal disease by stepwise regression, was the most important factor responsible for the observed decrease in birth weight (mean 384 gm vs nonteratogenic controls, p = 0.08). CONCLUSION: This study suggests that calcium channel blockers do not represent a major teratogenic risk.
AB - OBJECTIVE: Our purpose was to examine the potential teratogenicity of calcium channel blockers. STUDY DESIGN: Six teratogen information services prospectively collected and followed up 78 women with first-trimester exposure to calcium channel blockers. Pregnancy outcome was compared (by paired t test or χ2 analysis) with that of a control group matched for maternal age and smoking. RESULTS: There was no increase in major malformations (2/66 = 3.0% [calcium channel blockers] vs 0% [nonteratogenic controls], p = 0.27); a fivefold increase was ruled out (baseline 2%, α = 0.05, β = 0.20). The defects reported were attributable to maternal diabetes or coingestion of teratogens. The increase in preterm delivery (28% [calcium channel blockers] vs 9% [nonteratogenic controls], p = 0.003), attributed to maternal disease by stepwise regression, was the most important factor responsible for the observed decrease in birth weight (mean 384 gm vs nonteratogenic controls, p = 0.08). CONCLUSION: This study suggests that calcium channel blockers do not represent a major teratogenic risk.
KW - Calcium Channel blockers
KW - birth weight
KW - pregnancy
KW - pregnancy complications
UR - http://www.scopus.com/inward/record.url?scp=0029923576&partnerID=8YFLogxK
U2 - 10.1016/S0002-9378(96)70307-1
DO - 10.1016/S0002-9378(96)70307-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8633650
AN - SCOPUS:0029923576
SN - 0002-9378
VL - 174
SP - 823
EP - 828
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 3
ER -